文献速递炎症性肠病

硫嘌呤单药治疗对溃疡性结肠炎有效但对克罗恩病效果显著较差:英国炎症性肠病生物资源库11928例患者长期结局

Thiopurine monotherapy is effective in ulcerative colitis but significantly less so in Crohn's disease: long-term outcomes for 11 928 patients in the UK inflammatory bowel disease bioresource.
PubMed 文献 · Gut · 2020-10-01

该研究基于英国炎症性肠病生物资源库11928例(4968例溃疡性结肠炎、6960例克罗恩病)接受硫嘌呤单药维持治疗的患者,回顾性评估长期有效性。硫嘌呤单药在溃疡性结肠炎中有效率为52.7%(2617/4968),显著高于克罗恩病的34.2%(2378/6960)(p<0.0001);多变量分析校正后克罗恩病有效性仍低于溃疡性结肠炎(OR 0.47,95%CI 0.43至0.51,p<0.0001)。硫嘌呤不耐受与溃疡性结肠炎手术风险增加相关(HR 2.44,p<0.0001),对克罗恩病手术需求影响较温和(HR=1.23,p=0.0015)。

要点

  • 硫嘌呤单药维持治疗在溃疡性结肠炎中有效率为52.7%(2617/4968),克罗恩病为34.2%(2378/6960),差异显著(p<0.0001)。
  • 多变量分析校正治疗年代等变量后,克罗恩病有效性仍低于溃疡性结肠炎(OR 0.47,95%CI 0.43至0.51,p<0.0001)。
  • 硫嘌呤不耐受与溃疡性结肠炎手术风险增加相关(HR 2.44,p<0.0001),对克罗恩病手术需求影响较温和(HR=1.23,p=0.0015)。

核心结论

  • 硫嘌呤单药是溃疡性结肠炎的有效长期治疗,但在克罗恩病中效果显著较差。

研究设计与样本

  • 回顾性评估英国炎症性肠病生物资源库中11928例(4968例溃疡性结肠炎、6960例克罗恩病)以维持药物诱导缓解为目的起始硫嘌呤单药治疗的患者。

主要发现

  • 基于68132患者年暴露,硫嘌呤单药治疗期间溃疡性结肠炎有效2617/4968(52.7%),克罗恩病有效2378/6960(34.2%)(p<0.0001)。
  • 多变量分析校正治疗年代等变量后,硫嘌呤单药在克罗恩病中有效性低于溃疡性结肠炎(OR 0.47,95%CI 0.43至0.51,p<0.0001)。
  • 硫嘌呤不耐受与溃疡性结肠炎手术风险增加相关(HR 2.44,p<0.0001),对克罗恩病手术需求影响较温和(HR=1.23,p=0.0015)。

关键数值与推荐

  • 有效性定义为硫嘌呤治疗期间避免升级至生物制剂或手术。
  • 硫嘌呤单药治疗期间溃疡性结肠炎有效率为52.7%(2617/4968),克罗恩病为34.2%(2378/6960)(p<0.0001)。
  • 校正后克罗恩病有效性低于溃疡性结肠炎(OR 0.47,95%CI 0.43至0.51,p<0.0001)。
  • 硫嘌呤不耐受与溃疡性结肠炎手术风险增加相关(HR 2.44,p<0.0001),与克罗恩病手术风险相关(HR=1.23,p=0.0015)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Thiopurines are widely used as maintenance therapy in inflammatory bowel disease (IBD) but the evidence base for their use is sparse and their role increasingly questioned. Using the largest series reported to date, we assessed the long-term effectiveness of thiopurines in ulcerative colitis (UC) and Crohn's disease (CD), including their impact on need for surgery. DESIGN: Outcomes were assessed in 11 928 patients (4968 UC, 6960 CD) in the UK IBD BioResource initiated on thiopurine monotherapy with the intention of maintaining medically induced remission. Effectiveness was assessed retrospectively using patient-level data and a definition that required avoidance of escalation to biological therapy or surgery while on thiopurines. Analyses included overall effectiveness, time-to-event analysis for treatment escalation and comparison of surgery rates in patients tolerant or intolerant of thiopurines. RESULTS: Using 68 132 patient-years of exposure, thiopurine monotherapy appeared effective for the duration of treatment in 2617/4968 (52.7%) patients with UC compared with 2378/6960 (34.2%) patients with CD (p<0.0001). This difference was corroborated in a multivariable analysis: after adjusting for variables including treatment era, thiopurine monotherapy was less effective in CD than UC (OR 0.47, 95% CI 0.43 to 0.51, p<0.0001). Thiopurine intolerance was associated with increased risk of surgery in UC (HR 2.44, p<0.0001); with a more modest impact on need for surgery in CD (HR=1.23, p=0.0015). CONCLUSION: Thiopurine monotherapy is an effective long-term treatment for UC but significantly less effective in CD.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Stournaras E, Qian W, Pappas A, et al. Thiopurine monotherapy is effective in ulcerative colitis but significantly less so in Crohn's disease: long-term outcomes for 11 928 patients in the UK inflammatory bowel disease bioresource. Gut. 2020. PMID: 33004550. doi:10.1136/gutjnl-2019-320185

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。